CA3248134A1 - CYTOKINE COMPOSITIONS DESIGNED AND METHODS OF USE - Google Patents
CYTOKINE COMPOSITIONS DESIGNED AND METHODS OF USEInfo
- Publication number
- CA3248134A1 CA3248134A1 CA3248134A CA3248134A CA3248134A1 CA 3248134 A1 CA3248134 A1 CA 3248134A1 CA 3248134 A CA3248134 A CA 3248134A CA 3248134 A CA3248134 A CA 3248134A CA 3248134 A1 CA3248134 A1 CA 3248134A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- designed
- cell
- cytokine
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263298623P | 2022-01-11 | 2022-01-11 | |
| US63/298,623 | 2022-01-11 | ||
| US202363479178P | 2023-01-09 | 2023-01-09 | |
| US202363479177P | 2023-01-09 | 2023-01-09 | |
| US202363479176P | 2023-01-09 | 2023-01-09 | |
| US63/479,177 | 2023-01-09 | ||
| US63/479,176 | 2023-01-09 | ||
| US63/479,178 | 2023-01-09 | ||
| PCT/US2023/060508 WO2023137346A2 (en) | 2022-01-11 | 2023-01-11 | Designed cytokine compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3248134A1 true CA3248134A1 (en) | 2023-07-20 |
Family
ID=87279672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3248134A Pending CA3248134A1 (en) | 2022-01-11 | 2023-01-11 | CYTOKINE COMPOSITIONS DESIGNED AND METHODS OF USE |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250223330A1 (https=) |
| EP (1) | EP4463469A4 (https=) |
| JP (1) | JP2025502205A (https=) |
| KR (1) | KR20240164594A (https=) |
| CN (1) | CN119053616A (https=) |
| AU (1) | AU2023208031A1 (https=) |
| CA (1) | CA3248134A1 (https=) |
| IL (1) | IL314226A (https=) |
| MX (1) | MX2024008642A (https=) |
| WO (1) | WO2023137346A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL325764A (en) * | 2023-07-13 | 2026-03-01 | Outpace Bio Inc | Designed compositions of interleukin-2 cytokine and methods of use |
| WO2025212606A1 (en) * | 2024-04-01 | 2025-10-09 | Bio-Techne Corporation | Synthetic il-2 polypeptides and conjugates, compositions, and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210025522A (ko) * | 2018-06-25 | 2021-03-09 | 유니버시티 오브 워싱톤 | 강력하고 선택적인 인터루킨 모방체의 드 노보 디자인 |
| MX2021000801A (es) * | 2018-07-24 | 2021-04-12 | BioNTech SE | Agonistas de il2. |
| CN118510795A (zh) * | 2022-01-07 | 2024-08-16 | 苏州克睿基因生物科技有限公司 | 新型白介素-2多肽 |
-
2023
- 2023-01-11 WO PCT/US2023/060508 patent/WO2023137346A2/en not_active Ceased
- 2023-01-11 MX MX2024008642A patent/MX2024008642A/es unknown
- 2023-01-11 IL IL314226A patent/IL314226A/en unknown
- 2023-01-11 KR KR1020247026696A patent/KR20240164594A/ko active Pending
- 2023-01-11 AU AU2023208031A patent/AU2023208031A1/en active Pending
- 2023-01-11 JP JP2024541803A patent/JP2025502205A/ja active Pending
- 2023-01-11 US US18/727,646 patent/US20250223330A1/en active Pending
- 2023-01-11 CA CA3248134A patent/CA3248134A1/en active Pending
- 2023-01-11 EP EP23740805.9A patent/EP4463469A4/en active Pending
- 2023-01-11 CN CN202380027065.2A patent/CN119053616A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250223330A1 (en) | 2025-07-10 |
| KR20240164594A (ko) | 2024-11-19 |
| IL314226A (en) | 2024-09-01 |
| MX2024008642A (es) | 2024-09-23 |
| EP4463469A2 (en) | 2024-11-20 |
| AU2023208031A1 (en) | 2024-08-29 |
| EP4463469A4 (en) | 2026-01-14 |
| WO2023137346A2 (en) | 2023-07-20 |
| JP2025502205A (ja) | 2025-01-24 |
| CN119053616A (zh) | 2024-11-29 |
| WO2023137346A3 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7739547B2 (ja) | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 | |
| JP7551815B2 (ja) | Ｔ細胞療法を向上させるための、哺乳動物ｔ細胞の活性化により誘導可能な合成プロモーター（ｓｙｎ＋ｐｒｏ）の作製 | |
| JP7475088B2 (ja) | ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞 | |
| KR20230079259A (ko) | Kras 돌연변이 특이적 t세포 수용체의 스크리닝 및 항종양 용도 | |
| KR20150003306A (ko) | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 | |
| KR20210105947A (ko) | 나노트랜스포존 조성물 및 사용 방법 | |
| US20250223330A1 (en) | Designed cytokine compositions and methods of use | |
| CN109336980A (zh) | 一种靶向Muc1的嵌合抗原受体修饰T细胞及其用途 | |
| KR20220105161A (ko) | 항원 제시를 위해 세포를 2형 수지상 세포 성분으로 재프로그래밍하기 위한 조성물, 그 방법 및 용도 | |
| EP4132543A2 (en) | Human immune cells genomically modified to express orthogonal receptors | |
| US20210347842A1 (en) | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy | |
| CN116635427A (zh) | 嵌合抗原受体 | |
| CA3180251A1 (en) | Cytokine conjugates | |
| WO2021099576A1 (en) | Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines | |
| KR20260040610A (ko) | 설계된 인터루킨-2 사이토카인 조성물 및 사용 방법 | |
| WO2025059385A2 (en) | Anti-mesothelin chimeric antigen receptors and methods of use | |
| TW202434618A (zh) | 經設計之細胞激素組合物及使用方法 | |
| WO2023086517A1 (en) | Chimeric antigen receptors | |
| CA3133147A1 (en) | Core master regulators of glioblastoma stem cells | |
| WO2019157279A1 (en) | Mutant idh1 specific t cell receptor | |
| WO2025231228A1 (en) | Surrogate interferon agonists | |
| KR20240095172A (ko) | 항원 특이적 t 세포 수용체 및 키메라 공동자극 수용체의 조합 | |
| CN120882422A (zh) | 一种用于治疗血液癌症的试剂盒 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240710 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241203 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241203 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250103 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250103 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250103 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250220 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20250220 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251203 |